FILIP1L Recombinant Monoclonal Antibody

FILIP1L, also known as Downregulated in Ovarian Cancer 1 (DOC-1), represents a compelling target for researchers investigating tumor suppression mechanisms and cytoskeletal regulation. This protein interacts with filamin A and GPBP, positioning it at the intersection of cell adhesion, migration, and cancer biology. Its documented downregulation in ovarian cancer has made it a focus for studies exploring tumor progression and potential therapeutic targets.

This recombinant monoclonal antibody, clone 4H7G5, offers the consistency and reliability that demanding research protocols require. Generated against recombinant human FILIP1L protein and produced using recombinant technology with a human IgG1 framework, this antibody delivers sequence-defined specificity that eliminates the lot-to-lot variability often encountered with traditional hybridoma-derived reagents. Researchers can confidently incorporate this antibody into long-term studies knowing that performance characteristics will remain stable across multiple experiments.

Validation through immunohistochemistry demonstrates effective performance in paraffin-embedded human tissues. Testing in human small intestine tissue sections using a citrate buffer antigen retrieval protocol at pH 6.0 confirms reliable detection at dilutions ranging from 1:50 to 1:200, providing flexibility to optimize staining intensity for different tissue contexts. The antibody has also been validated for ELISA applications, expanding its utility across complementary detection platforms.

Supplied in a stabilizing buffer containing 50% glycerol and PBS at pH 7.4, this affinity-purified antibody maintains activity when stored at -20°C or -80°C. Whether investigating FILIP1L's role in ovarian cancer progression, exploring its interactions within the cytoskeletal network, or examining its expression patterns across human tissues, this antibody provides a dependable tool for advancing your research objectives.